The role of a tyrosine phosphorylation pathways in this response was further investigated examining platelets obtained from patients affected by CML treated with dasatinib, an Abl/Src dual specificity inhibitor. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.